Efficacy Differences in Aromatase Inhibitors for Advanced Breast Cancer
Author Information
Author(s): Bhatnagar A S
Primary Institution: World Wide Services Group Ltd
Hypothesis
Do differences in the potency of aromatase inhibitors translate into differences in efficacy benefits?
Conclusion
The review's claim that potency differences do not affect efficacy is contradicted by clinical trial results showing letrozole is more effective than anastrozole.
Supporting Evidence
- Letrozole was found to be superior to tamoxifen in all endpoints including survival analysis.
- Anastrozole and letrozole showed comparable results except for overall response rate, which was higher for letrozole.
- The efficacy of letrozole in ER/PgR-unknown tumors is consistent with its superiority over tamoxifen.
Takeaway
This study shows that some breast cancer treatments work better than others, especially for women whose cancer doesn't have certain hormone receptors.
Potential Biases
The author of the review may have conflicts of interest that are not disclosed.
Limitations
The review does not adequately address the efficacy of letrozole in patients with undetermined hormone receptor status.
Participant Demographics
The study involved postmenopausal women with advanced breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website